Abstract：Objective To evaluate the accuracy of β-amyloid protein 42 (Aβ42), total tau (t-tau) and phosphorylation tau (p-tau) proteins in cerebrospinal fluid in the diagnosis of Alzheimer’s disease (AD). Methods CNKI, WanFang, VIP, China Biology Medicine disc, PubMed, Embase, and Cochrane Library were searched for diagnostic tests of cerebrospinal fluid biomarkers in the diagnosis of AD, and the search time was from January 2000 to May 2020. According to the inclusion and exclusion criteria, the literatures were screened, the quality of the included literatures was evaluated, and the data were extracted for meta analysis using STATA15 software. Results A total of ten literatures were included. The results of meta-analysis showed that the sensitivity of cerebrospinal fluid Aβ42 in the diagnosis of AD was 0.85(95%CI [0.67, 0.94]), the specificity was 0.90(95%CI [0.83, 0.94]), the area under the summary receiver operating characteristic (SROC) curve (AUC) was 0.91(95%CI [0.89, 0.94]). The sensitivity of cerebrospinal fluid t-tau in the diagnosis of AD was 0.79(95%CI [ 0.65, 0.89]), the specificity was 0.83(95%CI [0.76, 0.89]), the AUC was 0.88(95%CI [0.85, 0.90]). The sensitivity of cerebrospinal fluid p-tau in the diagnosis of AD was 0.77(95%CI [0.69, 0.84]), the specificity was 0.82(95%CI [0.65, 0.91]), the AUC was 0.84(95%CI [0.80, 0.87]). Conclusion The accuracy of Aβ42, t-tau and p-tau in cerebrospinal fluid in the diagnosis of AD is relatively high. However, due to the limitation of the number of included studies and publication bias, more high-quality studies are needed to verify the results.
周英奕 倪敬年 魏明清 徐筱青 田金洲 时晶▲. 脑脊液Aβ、tau蛋白诊断阿尔茨海默病的系统评价和meta分析[J]. 中国医药导报, 2021, 18(11): 14-19.
ZHOU Yingyi NI Jingnian WEI Mingqing XU Xiaoqing TIAN Jinzhou SHI Jing▲. Systematic review and meta-analysis of Aβ and tau protein in cerebrospinal fluid in the diagnosis of Alzheimer’s disease. 中国医药导报, 2021, 18(11): 14-19.
[1] Association AS. 2018 Alzheimer’s disease facts and figures [J]. Alzheimers Dement，2018，14（3）：367-429.
[2] Jia J，Wang F，Wei C，et al. The prevalence of dementia in urban and rural areas of China [J]. Alzheimers Dement，2014，10（1）：1-9.
[3] Sattlecker M，Kiddle SJ，Newhouse S，et al. Alzheimer’s disease biomarker discovery using SOMA scan multiplexed protein technology [J]. Alzheimers Dement，2014，10（6）：724-734．
[4] Jack CR Jr，Bennett DA，Blennow K，et al. NIA-AA Research Framework：toward a biological definition of Alz-heimer’s disease [J]. Alzheimers Dement，2018，14（4）：535-562.
[5] Crowley TJ. Adolescents and substance-related disorders：research agenda to guide decisions on Diagnostic and Statistical Manual of Mental Disorders，fifth edition （DSM-V）[J]. Addiction，2006，101 Suppl 1：115-124.
[6] Sartorius N，Ustun TB，Korten A，et al. A Progress toward achieving a common language in psychiatry，Ⅱ：Results from the international field trials of the ICD-10 diagnostic criteria for research for mental and behavioral disorders [J]. Am J Psychiatry，1995，152（10）：1427-1437.
[7] Whiting PF，Rutjes AW，Westwood ME，et al. QUADAS-2：a revised tool for the quality assessment of diagnostic accuracy studies [J]. Ann Intern Med，2011，155（8）：529-536.
[8] 孙云闯，金海强，孙永安，等.脑脊液相关标志物检测在阿尔茨海默病痴呆诊断中的应用[J].中国神经精神疾病杂志，2018，44（12）：722-726.
[9] 秦绪珍，邱玲，李妹，等.脑脊液生物标志物在阿尔茨海默病与非痴呆神经疾病间的浓度比较[J].标记免疫分析与临床，2013，20（6）：369-373.
[10] Luo X，Hou L，Shi H，et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies [J]. J Neurochem，2013，127（5）：681-690.
[11] 方宇，张璐，朱红灿，等.脑脊液磷酸化tau蛋白及β淀粉样蛋白检测在老年期痴呆患者早期鉴别诊断中的价值[J].中国老年学杂志，2011，31（13）：2561-2562.
[12] 陈路明，徐斌，严家川.脑脊液β-淀粉样蛋白/磷酸化tau蛋白比值在鉴别诊断阿尔茨海默病与血管性痴呆中的价值[J].现代生物医学进展，2009，9（5）：922-924， 937.
[13] 薛海波，肖世富，孙云，等.脑脊液生物学标志物诊断阿尔茨海默病与血管性痴呆[J].中国现代神经疾病杂志，2007，7（3）：257-261.
[14] Ibach B，Binder H，Dragon M，et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients，disease controls and an age-matched random sample [J]. Neurobiol Aging，2006，27（9）：1202-1211.
[15] 郭洪志，梁临萍，杨望清.阿尔茨海默病病人的脑脊液蛋白指标改变[J].脑与神经疾病杂志，2003，11（1）：11-13.
[16] Lewczuk P，Esselmann H，Otto M，et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42，Abeta42/Abeta40 ratio and total tau [J]. Neurobiol Aging，2004，25（3）：273-281.
[17] 王琨，丁新生，程虹.阿尔茨海默病患者脑脊液TAU、Aβ_（1-40）、Aβ_（1-42（43））蛋白的检测及其临床意义[J].徐州医学院学报，2000（3）：115-118.
[18] 周英奕，张学婷，张磊，等.脑微透析技术在阿尔茨海默病诊治中的应用前景[J].中国脑血管病杂志，2016，13（10）：558-560.
[19] Palmqvist S，Insel PS，Stomrud E，et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease [J]. EMBO Mol Med，2019，11（12）：e11170.
[20] Bateman RJ，Xiong C，Benzinger TL，et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease [J]. N Engl J Med，2012，367（9）：795-804.
[21] 陈艳清，田喜慧，贾炳泉，等.阿尔茨海默病中Tau蛋白的异常磷酸化及其机制[J].脑与神经疾病杂志，2019， 27（10）：645-650.
[22] Andreasen N，Vanmechelen E，Vanderstichele H，et al. Cerebrospinal fluid levels of total-tau，phospho-tau and A beta 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment [J]. Acta Neurol Scand Suppl，2003，179：47-51.
[23] Nelson PT，Dickson DW，Trojanowski JQ，et al. Limbic-predominant age-related TDP-43 encephalopathy （LATE）：consensus working group report [J]. Brain，2019，142（6）：1503-1527.
[24] Dubois B，Hampel H，Feldman HH，et al. Preclinical Alzheimer’s disease：Definition，natural history，and diagnostic criteria [J]. Alzheimers Dement，2016，12（3）：292-323.
[25] Ferreira D，Perestelo-Pérez L，Westman E，et al. Meta-Review of CSF core biomarkers in Alzheimer’s disease：the state-of-the-art after the new revised diagnostic criteria [J]. Front Aging Neurosci，2014，3（6）：47.
京公网安备 11010502046598号